摘要
目的 分析高危子宫内膜癌卡铂和紫杉醇联合化疗后静脉血栓发生情况及影响因素。方法 选取中国人民解放军陆军第八十一集团军医院2015年1月至2020年6月收治的98例高危子宫内膜癌患者,均行卡铂+紫杉醇(TC)方案化疗,按照患者化疗后静脉血栓发生情况,将其分为发生组、未发生组,分析影响患者化疗后静脉血栓发生的相关因素。结果 患者静脉血栓发生率为17.35%。其中锁骨下静脉(7例,41.18%)最为常见。FIGO分期Ⅲ期、化疗前D-二聚体≥0.5 mg/L、传统穿刺、肘窝穿刺是影响高危子宫内膜癌TC方案化疗后静脉血栓的独立危险因素,穿刺贵要静脉为保护因素(P <0.05)。结论 高危子宫内膜癌患者TC方案化疗后静脉血栓发生上肢静脉的风险较高,其影响因素包括临床分期、凝血功能状态、穿刺方法及穿刺部位、血管选择等。
Objective To analyze the incidence and influencing factors of venous thrombosis after carboplatin and paclitaxel combined chemotherapy in high-risk endometrial carcinoma. Methods A total of 98 patients with highrisk endometrial cancer who were treated in our hospital were selected and treated with carboplatin + paclitaxel(TC)chemotherapy. According to the occurrence of venous thrombosis after chemotherapy, they were divided into the occurrence group and the non-occurrence group, and the influence of chemotherapy was analyzed. Logistic multivariate regression analysis was used to summarize the related factors affecting the occurrence of venous thrombosis. Results The incidence of venous thrombosis in patients was 17.35%. The most common site of thrombosis was the subclavian vein(7 cases, 41.18%).FIGO stage Ⅲ, D-dimer ≥ 0.5 mg/L before chemotherapy, traditional puncture, and cubital puncture were independent risk factors for venous thrombosis after TC chemotherapy for high-risk endometrial cancer, and puncture of the precious vein was a protective factor(P < 0.05). Conclusion Patients with high-risk endometrial cancer have a higher risk of venous thrombosis in upper extremity veins after chemotherapy with TC regimen, and the influencing factors include clinical stage,coagulation function status, puncture method, puncture site, and blood vessel selection.
作者
冯延
徐燕
梁涛
李海
FENG Yan;XU Yan;LIANG Tao;LI Hai(Department of General Medicine,Affiliated Tumor Hospital of Chongqing University,Chongqing 400030,China)
出处
《中国妇产科临床杂志》
CSCD
2022年第3期284-286,共3页
Chinese Journal of Clinical Obstetrics and Gynecology
基金
四川省教育厅2018年度科研计划(18ZA0166)。
关键词
子宫内膜癌
卡铂
紫杉醇
化疗
静脉血栓
endometrial carcinoma
carboplatin
paclitaxel
chemotherapy
venous thrombosis
